Loading
A phase 2 trial of Rocapuldencel-T run by GU Research Network, LLC, withdrawn before enrolling.
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT02662634 by GU Research Network, LLC, started 2016-03. Conditions recorded: Non-small Cell Lung Cancer (NSCLC). Interventions recorded: AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol and Radiation Therapy.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/